ALS arises from a combination of genetic and environmental factors, and in most cases no single cause can be identified.

• Genetic mutations: Around 10% of cases are familial, linked to genes such as SOD1, C9orf72, TARDBP, and FUS. The remaining ~90% are sporadic, with no clear inherited pattern.
• Protein misfolding and aggregation: Abnormal accumulation of proteins like TDP-43 inside motor neurons is a hallmark of most ALS cases and appears to disrupt normal cell function.
• Oxidative stress: Excess free radicals can damage neuron structures and accelerate cell death.
• Glutamate excitotoxicity: Elevated glutamate levels can overstimulate motor neurons, contributing to their degeneration.
• Neuroinflammation: Activated immune cells in the brain and spinal cord (microglia and astrocytes) are thought to accelerate motor neuron loss rather than simply respond to it.
• Age and sex: Risk increases with age, and men have a somewhat higher incidence than women, particularly before age 65.
• Possible environmental links: Studies have explored associations with military service, heavy metal exposure, certain pesticides, and repetitive head trauma, though evidence remains mixed.

Understanding these mechanisms is central to why regenerative approaches focus on reducing inflammation and oxidative stress, not just replacing lost cells.

ALS symptoms usually begin subtly and worsen gradually. Presentation varies depending on whether the disease starts in the limbs (limb-onset) or affects speech and swallowing first (bulbar-onset).

Early signs

• Muscle twitching (fasciculations), cramping, or stiffness
• Weakness in a hand, foot, arm, or leg
• Slurred or slowed speech
• Difficulty swallowing or unexplained weight loss
• Fatigue that’s disproportionate to activity

As the disease progresses

• Increasing muscle weakness and wasting (atrophy)
• Loss of fine motor control (buttoning a shirt, writing)
• Difficulty walking or maintaining balance
• Shortness of breath, especially when lying down
• Cognitive or behavioral changes in a subset of patients (ALS-FTD spectrum)

⚠️ Persistent, unexplained weakness, slurred speech, or swallowing difficulty warrants prompt neurological evaluation — early diagnosis allows more treatment and care-planning options.

There is no single test that confirms ALS; diagnosis is made by ruling out other conditions and identifying a consistent pattern of upper and lower motor neuron damage.

• Clinical neurological exam: Assesses reflexes, muscle strength, tone, and coordination.
• Electromyography (EMG) and nerve conduction studies (NCS): Detect abnormal electrical activity in muscles and identify the extent of motor neuron involvement.
• MRI of the brain and spine: Used to exclude structural causes such as tumors, herniated discs, or stroke that can mimic ALS.
• Blood and urine tests: Rule out metabolic, infectious, or autoimmune conditions with overlapping symptoms.
• Genetic testing: Recommended for patients with a family history, to identify mutations such as SOD1 or C9orf72.
• Lumbar puncture (occasionally): Helps rule out inflammatory or infectious neurological disease.

Because ALS shares features with other neuromuscular disorders, diagnosis is often made using the revised El Escorial or Gold Coast criteria, applied by a neurologist experienced in motor neuron disease, sometimes over multiple visits as the pattern of weakness becomes clearer.

How stem cell therapy is being studied for ALS

Investigational stem cell approaches for ALS generally fall into three categories:

1. Mesenchymal stem cells (MSCs) — typically sourced from the patient’s own bone marrow or adipose tissue, studied for their ability to secrete neurotrophic and anti-inflammatory factors.
2. Neurotrophic factor–secreting MSCs (e.g., the NurOwn/debamestrocel platform) — MSCs cultured under conditions that boost their secretion of nerve growth-supporting molecules before being reinjected.
3. iPSC-derived neural progenitors — an earlier-stage research approach exploring whether lab-grown neural precursor cells can support the motor neuron environment.

None of these are FDA-approved treatments for ALS. They remain investigational, and outcomes in published trials have been mixed — some studies show signals of slowed functional decline in specific patient subgroups (e.g., earlier-stage disease), while others have not met their primary endpoints.

What a typical evaluation and protocol involves at Viezec

• In-depth review of neurological history, EMG/NCS results, and current ALSFRS-R functional score
• Bloodwork and imaging to confirm eligibility and rule out contraindications
• Discussion of realistic expectations, based on current published evidence — not guarantees
• If appropriate, cell collection (bone marrow or adipose-derived), laboratory processing, and administration under medical supervision
• Structured follow-up to track function, safety, and any adverse events

What this is not: a promised cure, a replacement for standard ALS care (riluzole, edaravone, respiratory support, multidisciplinary clinics), or a guaranteed way to reverse existing paralysis.

Discuss Eligibility With Our Team

Explore our complete range of stem cell therapy services for neurological, orthopedic, autoimmune, and degenerative conditions.

Investigational stem cell products for ALS are typically administered by one of the following routes, chosen based on the patient’s disease pattern, stage, and treatment goals:

• Intrathecal injection (into the cerebrospinal fluid via lumbar puncture): The most studied route in ALS trials, intended to bring cells or their secreted factors closer to the spinal motor neurons.
• Intravenous (IV) infusion: A systemic delivery route sometimes used alongside intrathecal dosing to support broader anti-inflammatory effects.
• Intramuscular injection: Used in some earlier-phase protocols targeting specific muscle groups.

All procedures should be performed in a controlled clinical setting, with cell products processed in a GMP-compliant laboratory and administered by clinicians experienced in neurological procedures. Patients are typically monitored for several hours post-procedure for immediate reactions, with scheduled follow-up to assess for delayed effects.

Patients and families considering this treatment often ask what “improvement” could realistically look like. Based on the published clinical trial literature (not guarantees for any individual):

• Functional stability: Some studies report a slower rate of decline on the ALSFRS-R functional rating scale in treated groups versus placebo, particularly in early-stage or slower-progressing patients — though this finding has not been consistent across all trials.
• Reported subjective changes: Some trial participants and case reports describe modest, temporary improvements in grip strength, speech clarity, or energy level, but these are not universal and are not considered proof of disease-modifying effect on their own.
• No trial to date has demonstrated reversal of established paralysis or muscle wasting.

We track outcomes using standardized measures (ALSFRS-R, spirometry/FVC, manual muscle testing) rather than subjective impression alone, and we share both positive and negative findings from each assessment with the patient and their care team.

Rather than trying to replace lost motor neurons directly — which remains extremely difficult given how specialized and long these cells are — most investigational stem cell approaches for ALS aim to support the environment around surviving neurons:

• Neurotrophic factor secretion: MSCs can release growth factors (e.g., GDNF, BDNF, VEGF) that support neuron survival and may encourage local repair processes.
• Immunomodulation: Stem cells can shift the local immune response away from the chronic inflammatory state associated with microglial and astrocyte activation in ALS.
• Reduction of oxidative stress: Some preclinical studies suggest MSC-derived factors can lower oxidative damage in the motor neuron environment.
• Paracrine signaling over direct engraftment: Most current evidence points to these benefits (where observed) coming from the molecules stem cells secrete, rather than the cells becoming new, functioning motor neurons themselves.

This mechanism is why current research emphasizes “slowing progression” and “supporting function” as realistic goals, rather than regeneration of already-lost motor neurons.

At [Clinic Name], our commitment to ALS patients and their families is:

• Honest eligibility screening — we will tell you plainly if we do not believe you are a suitable candidate, or if a registered clinical trial may serve you better than a fee-based protocol.
• Evidence-based counseling — every conversation about expected outcomes is grounded in published trial data, not marketing language.
• Medical safety first — procedures performed under qualified neurological and regenerative medicine supervision, with full informed consent.
• No guarantees of cure — because none currently exist for ALS, from us or any provider.
• Coordinated, not competing, care — we work alongside your existing neurologist and ALS clinic rather than asking you to replace them.

Learn More About Our Approach

Results following investigational stem cell administration are tracked through structured, scheduled reassessment rather than one-time patient impression:

• Baseline assessment: ALSFRS-R score, forced vital capacity (FVC), grip strength, and functional independence measures recorded before treatment.
• Follow-up intervals: Typically at 1, 3, 6, and 12 months, using the same standardized measures.
• Reporting to patients: Each patient receives a written summary of their own trend data — whether it shows stability, decline, or improvement — so decisions about further treatment are based on their individual response, not general marketing claims.

Because ALS progression rates vary widely between individuals even without treatment, we are careful not to attribute any single patient’s stability or change solely to the intervention without appropriate context.

Testimonials

Individual experiences shared by patients and families. These reflect personal impressions of their care journey and are not indicative of typical or guaranteed clinical outcomes.

Michael R. – Boston, USA – January 2020 – ⭐⭐⭐⭐☆
“ALS made daily life difficult for our family. The Viezec team explained our options clearly and stayed closely involved throughout the evaluation and treatment process.”

Arjun P. – Bangalore, India – March 2020 – ⭐⭐⭐⭐⭐
“Living with ALS is not easy. Viezec’s medical staff were attentive and communicative at every stage, which meant a great deal to me and my family.”

Helena S. – Berlin, Germany – September 2021 – ⭐⭐⭐⭐☆
“ALS has been a difficult diagnosis to manage. Viezec’s medical staff gave me hope and genuine care throughout my treatment journey.”

Ahmed K. – Riyadh, Saudi Arabia – November 2021 – ⭐⭐⭐⭐⭐
“The team at Viezec took time to walk me through what to expect before, during, and after treatment. I appreciated their honesty and support.”

Laura T. – Toronto, Canada – February 2022 – ⭐⭐⭐⭐☆
“ALS has been a challenging journey for our family. Viezec’s coordinators kept us informed and supported us with clear, compassionate communication.”

Pedro M. – Lisbon, Portugal – July 2022 – ⭐⭐⭐⭐⭐
“Between physiotherapy and my care at Viezec, I felt genuinely supported in managing daily life with ALS. The team’s attentiveness made a real difference.”

Amina Z. – Casablanca, Morocco – April 2023 – ⭐⭐⭐⭐☆
“My husband’s ALS has been hard on our whole family. Viezec’s team stayed in close contact with us throughout his care and brought us hope.”

George L. – Melbourne, Australia – October 2023 – ⭐⭐⭐⭐⭐
“The care I received at Viezec gave me the courage to continue with physiotherapy. Their team was thorough and encouraging every step of the way.”

Yasmin H. – Dubai, UAE – January 2024 – ⭐⭐⭐⭐☆
“ALS has affected my father’s daily life significantly. Viezec’s team was patient with our questions and thorough in explaining his care plan.”

Roberto C. – Rome, Italy – May 2025 – ⭐⭐⭐⭐⭐
“Facing ALS is difficult, but Viezec’s care gave me renewed hope. The team’s outstanding attention throughout the process meant a lot to me.”

Published clinical trials of MSC-based therapies in ALS have shown mixed results — some report slower functional decline in specific patient subgroups over 6–12 months, while others have not met their primary endpoints compared to placebo. We track every patient’s individual ALSFRS-R and FVC trend and will share your own data with you at each follow-up, rather than presenting a single ‘success rate’ that may not reflect your specific case.

The information on this page is provided for educational purposes and does not constitute medical advice, diagnosis, or a treatment recommendation for any individual. Amyotrophic lateral sclerosis affects each patient differently, and general information cannot substitute for an in-person evaluation by a qualified neurologist.

• What this page does: Explains ALS, current investigational stem cell research, and general considerations for evaluating treatment options.
• What this page does not do: Guarantee any specific outcome, replace standard neurological care, or serve as a substitute for informed consent counseling prior to any procedure.
• Regulatory status: Stem cell-based interventions for ALS beyond currently approved uses are investigational. Depending on jurisdiction, they may only be legally offered within registered clinical trials or specifically licensed research/compassionate-use frameworks. [Clinic Name] will confirm the applicable regulatory pathway for your case before proceeding.
• If symptoms suddenly worsen — particularly breathing difficulty — seek emergency medical care immediately.

Request a Medical Evaluation